Swedish firm combines densitometry with digital mammography
Sectra hopes to strengthen its position in women’s healthcare with the availability of osteoporosis testing as part of its digital MicroDose mammography system.
Sectra hopes to strengthen its position in women's healthcare with the availability of osteoporosis testing as part of its digital MicroDose mammography system.
The Swedish company is best known for its PACS but also involved in mammography. It showcased at ECR its bone mineral densitometry software integrated with a full-field digital mammography (FFDM) system.
"Women come in for mammography screening. Why not also put their hands on the detector and check for osteoporosis?" said Staffan Bergstrom, Sectra vice president of marketing. "It is a neat business model."
The company has installed about a half-dozen of the FFDM systems featuring amorphous silicon flat detectors at sites in Europe. A few research sites are also operating in the U.S. The bone densitometry capability will be offered as an option on future sales in Europe.
The company has not yet determined a price for this option, although Bergstrom says it will not be high. Its availability will help differentiate the MicroDose product from competitors, while offering an additional revenue stream for practitioners who choose this capability.
"For the women, since they are already there for a mammography checkup, it makes sense to check for the risk of osteoporosis," he said. "It is the same target group: women over 40."
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
